by Mark L. Ratner
The motto for TheraSense Inc. could well be "Test it and they will come." The only pure play among...
TheraSense's Sweet Spot
TheraSense is making inroads in the $4 billion diabetes testing market. Its FreeStyle glucose meter system is a quality product--perhaps the best in its class. FreeStyle has gained 6% of the US meter market in less than two years, and that share still appears to be increasing. But in the six years since the company's founding, the market has changed; more than ever, glucose meters are viewed as a consumer item. And TheraSense is competing with much larger companies in the space. TheraSense has already seen the marketing of blood glucose meters change dramatically in the past three years. Should the FreeStyle line wither in the face of big-company competition, it would have little left to drive its stock price.
More from Business Strategy
• By
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
• By
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
• By
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
• By
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
More from In Vivo
• By
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
• By
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
• By
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.